You must successfully complete the post activity assessment with a score of 70% or better prior to completing the evaluation and application for credit.
0 of 15 questions completed
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading…
You must sign in or sign up to start the assessment.
You must first complete the following:
0 of 15 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
You did not successfully complete this post-activity assessment.
You successfully completed this post-activity assessment.
Proceed to the Evaluation and application for credit to receive your certificate.
What makes a cancer a good CAR T-cell candidate?
Which step is not part of the CAR T cell engineering/manufacturing process?
Which of the following is not an FDA approved CAR T-cell therapy?
Which indication is not an FDA–approved indication for CAR T-cell therapy at this time?
Which were trials done to evaluate CAR T-cell therapy for patients with diffuse large B-cell lymphoma (DLBCL)?
Which of the following is a requirement of a certified CAR-T treatment facility?
Which of the following is/are true regarding bridging chemotherapy in the CAR T-cell treatment process?
On the day of infusion of CAR T-cells, patients should be given prophylactic antibiotics for infection risk.
Which is true of Cytokine Release Syndrome (CRS)?
What is the recommended treatment for Grade 3 neurotoxicity associated with CAR T-cell therapy?
Potential late (Post 30 days) toxicities associated with CAR T-cell therapy do not include:
Antimicrobial prophylaxis post CAR T-cell therapy includes:
Which patients are considered good candidates for CAR T-cell therapy?
All 3 approved CART products are available only:
The Leukemia & Lymphoma Resources available include: